A start-up enterprise seeks to make drugs for treating rare diseases more readily available to physicians and patients in Europe. . . . → Read More: Company to Boost Orphan Drugs in Europe
|
|||||
A start-up enterprise seeks to make drugs for treating rare diseases more readily available to physicians and patients in Europe. . . . → Read More: Company to Boost Orphan Drugs in Europe A company developing non-invasive ultrasound treatments for treating skin disorders and removing tattoos received a patent for its technology. . . . → Read More: Patent Awarded for Focused Ultrasound Skin Treatments A company making precision therapies for neurological disorders is acquiring rights to a compound first designed as a treatment for cancer, inflammation, and oxidative stress. . . . → Read More: Drug Licensed for Precision Autism Spectrum Therapies A biotechnology company developing gene-edited therapies for bacterial infections in the gut received a U.S. patent for viruses engineered as treatments. . . . → Read More: Patent Issued for Crispr-Edited Viruses in Microbiome A new company is acquiring a technology using genome-edited tadpoles that finds current drugs addressing precise genetic conditions underlying rare diseases. . . . → Read More: Start-Up Licenses Gene-Edited Drug Discovery Tech. A genetic technology for synthesizing cannabinoid compounds without cannabis cells was licensed to a company spun-off from the lab that developed the process. . . . → Read More: Cannabinoid Synthesis Process Licensed to Spin-Off Company Two companies agreed to license technologies from academic labs in the U.S. and U.K. for developing faster and more sensitive at-home tests for Covid-19 infections. . . . → Read More: Univ. Labs Ink Licensing Deals for Covid-19 Tests A biotechnology company received a patent for its engineered viruses to deliver gene-edited treatments to combat bacterial infections in the microbiome. . . . → Read More: Patent Issued for Anti-Bacterial Viruses with Crispr Payloads Two companies working in women’s reproductive health are developing a new non-hormonal contraceptive that works in cervical mucous membranes. . . . → Read More: Women’s Health Companies Partner on New Contraceptive A biotechnology company is licensing a gene-editing enzyme to Novartis to create treatments for inherited blood disorders such as sickle cell disease. . . . → Read More: Biotech in $1.5B Gene-Editing Tech License Deal |
|||||
Copyright © 2024 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |